Latest News List

Latest News

Drug International Limited launched Osinib

Osinib (Osimertinib INN) 80 mg Tablet is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.

© Copyright Drug International Ltd. 2019 Designed and Developed by ATI Limited.